Recruiting

Observational Study

Sponsor:

iRxReminder

Code:

NCT06011408

Conditions

Tardive Dyskinesia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TDtect

Study Details

Brief summary:

The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.

Conditions

Tardive Dyskinesia

Study ID

NCT06011408

Start date

May 30, 2023

Status verified date

Mar, 2024

Completion date

Dec 31, 2024

Anticipated

Primary completion date

Nov 30, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

For the non-TD group:

1. Prescribed and taking an antipsychotic medication for 90-days or longer.
2. Tardive Dyskinesia symptoms if present are not from Parkinsons, Tourette's syndrome, Huntington disease.
3. Signed an informed consent.
4. Speaks English fluently.

Exclusion Criteria:

1. Suffered a moderate or severe head injury in the last year;
2. History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol.
3. Severe visual impairment that is cannot be corrected by glasses or contacts.

Study Design

Enrollment

300 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Screening

Interventions and Outcome Measures

Arms

other: Taking antipsychotic medication with Tardive Dyskinesia

other: Taking antipsychotic medication without Tardive Dyskinesia

Interventions

TDtect

Collecting video data on abnormal movement

Primary outcome measure

  • AIMS Score [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Locations

Fermata Helath

Recruiting

Brooklyn, New York, United States, 10038

Contacts

Principal Investigator:

Owen Muir, M.D.

Charak Research Center

Recruiting

Garfield Heights, Ohio, United States, 44125

Contacts

Principal Investigator:

Rakesh Ranjan, M.D.

More Information

Sponsor

iRxReminder

Last update posted

Mar 12, 2024

Last verified

Mar, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by iRxReminder on 2024-03-12.